Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (11112)	4/19/2012 2:58:49 PM
From: Mammon	3 Recommendations Read Replies (1) \| Respond to of 13111

nttg, I believe you are incorrect in your "everyone else in biotech is publishing" meme. According the following well-researched article, during the years the author compiled data about FDA trials, 76 percent of pivotal trials that led to FDA approval were published in peer-reviewed journals. But the key take-away from this article for the purposes of this discussion is that 68 percent of those studies were published in peer-reviewed publications AFTER FDA approval. [And perhaps for the purpose of spurring sales, IMHO.] sciencebasedmedicine.org If anyone is aware of more current data than for the years covered in the article, I would be interested in reading it, of course.